Brent Rose Lab


The major focus of Dr. Rose’s lab is on population sciences research, in particular analyses of large databases of prostate cancer patients. Recent work includes assessment of the impact of pre-diagnostic 5α-reductase inhibitor, the association between dementia and androgen deprivation therapy in prostate cancer patients undergoing definitive RT and the safety of active surveillance in African-American men with low-risk prostate cancer. His group focuses on multiple large databases including VINCI and the Million Veteran Project within the Veterans Administration system.

ALT TEXT HERE

PEOPLE

PEOPLE


PUBLICATIONS

PUBLICATIONS

      

Lab News

Lab News

           

DR. ROSE’S RESEARCH IS SUPPORTED IN PART BY 4-YEAR $806K DEPARTMENT OF DEFENSE (DOD) GRANT

Featured Articles

ALT TEXT HERE

Adverse Impact of Pre-Diagnostic 5α-Reductase Inhibitors

This study demonstrated that pre-diagnostic 5α-reductase inhibitors (5-ARI) are associated with delayed biopsies and worse cancer-specific outcomes in men with prostate cancer

Read Now
ALT TEXT HERE

No Association between ADT and Dementia in Prostate Cancer Patient Undergoing RT

This study found no association between androgen deprivation therapy (ADT) and any form of dementia in over 45K prostate cancer patients treated with definitive RT

Read Now
ALT TEXT HERE

3-Month Post-Treatment PSA Level as a Prognostic Biomarker

This study found that the 3-month post-treatment PSA level was a strong biomarker for prostate-cancer specific outcomes in prostate cancer patients undergoing definitive RT and androgen deprivation therapy (ADT).

Read Now
Do Not Show